Skin biopsies of patients with AD show an overexpression of IL-13 as compared to healthy individuals

The objective of the study is to compare clinical IL-13 monoclonal antibodies’ binding affinities and cell-based functional activities

The differences in molecular characteristics between these IL-13 therapies may help in the understanding of the differences seen in the clinical trial results, though head-to-head studies have not been conducted

Lebrikizumab has a higher binding affinity and in vitro potency than other IL-13 therapies compared in the study